$DOCN CEO just confirmed my 2026 rerate call. I said the market was pricing in only ~14% CAGR through 2028 while I expected closer to 20% by 2027. This morning the CEO confirmed it: “This momentum gives us confidence that we can achieve our 18–20% growth targets for 2027 a year ahead of schedule, in 2026.” The stock is up over 10% following earnings.
$DOCN JUST CLEARED $40 & MY 2026 RERATE STORY IS PLAYING OUT I’ve been pounding the table on this name since the $20s because the market completely misunderstood what it is. It’s been priced like a slow-growth AWS clone at 10x EBITDA, but Gradient AI is turning into their entry point for AI workloads. That shift is driving higher ARPU, lower churn & a move toward enterprise-grade usage. Utilization has already started to inflect the last couple of quarters which is why I think rev growth pushes back above 20% by 2027 with 35% EBITDA margins while the Street still models 14%. Nobody was talking about this name until the recent breakout. That’s exactly why conviction & doing your own work matter.
Replying to @StockSavvyShay
Big win! #DOCN

Nov 5, 2025 · 2:10 PM UTC